A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
Parkinson’s patients and their families are increasingly turning to genetic testing to learn more about their disease or risk of passing it on. But testing is complex, and counseling is advised.
COVID patients who remain unresponsive after receiving respiratory support may require long time periods to regain consciousness; delays are related to blood oxygen levels.
A new study shows how cellular “housekeeping” protects some neurons against the toxic proteins of Alzheimer’s disease and suggests new treatment possibilities.
Increasingly, transformative therapies are being launched via startups emerging from university research labs, including those at Columbia’s Vagelos College of Physicians and Surgeons.
Scientists initially believed Alzheimer's would be a simple, straightforward problem to solve, but now Columbia researchers are looking for unusual and untried solutions.
Columbia neurologists found that a test used to measure Alzheimer's disease proteins in spinal fluid can be used to determine whether patients have the disease or other forms of dementia.
A newly discovered function for the ApoE4 gene, the strongest genetic risk factor for Alzheimer’s disease, may help explain how the gene causes cognitive decline.